Gradually, shortage of crystalline and isopaneous insulin is resolved

The Ministry of Health He announced that gradually begins to resolve shortages with the crystalline and isopan human insulin. There was presented difficulties in the supply at the national level.

According to the entity the other types of insulin, Known as analogues, they maintain a stable marketing in the national territory.

“Within the framework of the supply monitoring that the ministry performs, it was identified that human insulins (crystalline and isopane) were declared as ‘shortages’ medications by the Invim Elyxim Biopharmaceutical, Biocon and Novo Nordisk), currently only Pisa Pharmaceutical These products due to the loss of commercial interest of the other three holders, ”said the Ministry of Health.

Loading …

Read more: Colombia sends a protest letter to Ecuador for deportation of connationals prisoners

He stressed that in the case of medicines of the pharmaceutical company Novo Nordisk, That historically supplied more than 50% of the market, the marketed units has been decreasing and temporarily suspended the supply since the last quarter of 2024 due to manufacturing problems, without informing estimated return date.

“For this reason, since October 2024, human insulins (crystalline and isopane) have been included in the list of vital medicines not available to INVIMA. It is important to highlight that crystalline human insulin is mainly used In the intrahospitary field as a first choice medication for hyperglycemia management, ”he explained.

He assured that in the outpatient environment, its use has been largely replaced by analog insulins, Situation similar to that of isopan human insulin.

“As a result, the demand for these medications has decreased and, due to their lower cost compared to analog insulins, the industry has shown less interest in its commercialization. However, the fact that their profitability is low, does not imply that these medications are not important for health care,” he said.

The Ministry of Health said that in the face of this situation in a work together with the INVIMA, it has monitored the headline holders and Evaluated import interest under the vital medicine modality not available.

“As a result, Pisa Pharmaceutics expressed its ability to supply the national market, both with a product with sanitary registration and under the vital modality not available. This information was provided during the work table, with the participation of actors in the health sector,” he said.

It may interest you: War between Thailand and Cambodia complete three days and leaves more than 30 dead

The Ministry of Health He indicated that the update of the availability information given by this laboratory is as follows:

Crystalline Human Insulin: They have a availability for marketing 14,900 units. In addition, INVIMA authorized the import of 70,000 units under the vital medicine modality not available.

Isopan Human Insulin (NPH): They have a availability for marketing 23,000 units, and the Invima authorized the import of 80,000 units low The vital modality not available.

These actions contribute to strengthening the availability of human insulins in the country during the next months.

As for analog insulins, the previously communicated information is reiterated:

Novo Nordisk, the only bidder of insulins Swallowing, swallow + liraglutida, detemir and aspart, as well as the medicine glucagon injectable solution, it maintains availability and commercialization according to the current demand.

Sanofi Aventis announced that it retains a stable availability and commercialization of insulin glargina, insulin Glulisine and the insulin combination Glargina + Lixisenatide.